Table 1. Effect of different treatments on body weight, as well as food and water intake in n-STZ diabetic rats.
Experimental Groups | Body weight (gm) | Food intake (gm/rat/day) | Water intake (ml/rat/day) |
---|---|---|---|
Normal control | 225.8± 5.13 | 19.68 ± 0.93 | 60.23 ± 2.08 |
Diabetic control | 320.6 ± 8.34* | 41.24 ± 1.33* | 147.51 ± 3.62* |
Galan 2.5 | 281.5 ± 6.89# | 34.16 ± 0.90*#ϕ | 113.21 ± 2.79*#ηϕ |
Galan 5 | 272.2 ± 5.16# | 30.21 ± 1.10*# | 95.84 ± 3.42*# |
Galan 10 | 275.2 ± 6.60# | 27.45 ± 0.77*# | 86.67 ± 2.39*# |
Vilda 3 | 304.6 ± 7.51* | 39.57 ± 1.55* | 126.16 ± 3.46*#Ψ |
Vilda 10 | 308.6 ± 7.94* | 40.26 ± 1.58* | 110.25 ± 3.77*#Ψ |
Vilda 30 | 306.1 ± 7.50* | 37.89 ± 1.21* | 90.43 ± 2.76*# |
Galan 5+Vilda 30 | 268.4 ± 6.31#Ψa | 23.13 ± 0.88# ηΨb | 77.92 ± 2.80*#ηΨ |
Galantamine (Galan 2.5, 5 & 10 mg/kg), vildagliptin (Vilda 3, 10 & 30 mg/kg) and their combination (Galan 5 & Vilda 30) were gavaged orally for four weeks. Values are means of 10 rats ± S.E.M as compared with normal control (*), diabetic control (#), Galan5 (η), Galan10 (ϕ) and Vild30 (Ψ)-treated groups (one-way ANOVA followed by Tukey post hoc test) at P < 0.05. (a) Additive and (b) synergistic interactions when Galan5 and Vilda30 were combined using Factorial Design.